Licensing & Co-Development
Generic｜ 505(b)(2)｜ clinical-stage new drug
Licensing & Co-Development
When pharmaceutical assets move toward international markets, successful licensing depends on aligning each product with the right partners, the right market positioning and the right strategy.
Apexray focuses on the strategic considerations behind international licensing for generics, 505(b)(2) products and clinical-stage assets — including how different markets evaluate value, risk, positioning & partnership fit across Europe, the US, Japan, Asia and other key regions.
Key areas of expertise:
Asset and value assessment – including target indication selection and market prioritisation for different regions.
Evaluation of market opportunity and competitive landscape – analysing market size, pricing bands and existing or emerging treatment options to define realistic entry scenarios.
Licensing territory design and deal economics – including upfronts, milestones, royalties.
Partner landscape mapping and decision-maker profiling for licensing and co-development discussions.
Preparation of structured BD materials and documentation to support internal reviews and due-diligence processes.
Contact
For professional enquiries or networking related to BD and licensing, feel free to get in touch via the form below.